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Letter by Scheitz et al Regarding Article, “Randomized Controlled Trial 
of Early Versus Delayed Statin Therapy in Patients With Acute 
Ischemic Stroke: ASSORT Trial (Administration of Statin on Acute 
Ischemic Stroke Patient)” 
 
To the Editor: 
Based on the evidence from the SPARCL trial (Stroke Prevention by Aggressive Reduction in 
Cholesterol Levels), statins are generally recommended to reduce stroke and cardiovascular events 
among patients with recent atherothrombotic stroke or transient ischemic attack.1 Because of rapid 
cholesterol-independent vasoprotective effects of statins shown in experimental settings,2 there is 
an ongoing discussion whether it might be beneficial to start statin treatment as early as possible. 
 
Adding to this discussion, we read with interest the results from the randomized, controlled ASSORT 
(Administration of Statin on Acute Ischemic Stroke Patient) trial.3 Although the trial missed the 
primary endpoint on improvement of modified Rankin Scale at 3 months, there were no safety 
concerns attributable to early statin administration. This is in line with the STARS trial (Stroke 
Treatment With Acute Reperfusion and Simvastatin) published last year.4 Unfortunately, the STARS 
trial had to stop early for slow enrolment and was underpowered to detect statistically robust 
effects. In ASSORT, the assumed effect size of statin treatment was probably not realistic, and the 
inclusion of mildly affected patients with small infarctions led to beneficial outcomes in the vast 
majority of patients although analysis of outcome by considering the full range of the modified 
Rankin Scale mitigates case-mix limitations. We would like to draw the attention to a recently 
published analysis from the Virtual International Stroke trials Archive (vistacollaboration.org).5 
Patients with early statin use within 3 days after stroke onset (n=626) were compared with patients 
with later or no statin use. Matching for age, sex, severity measures, and use of other oral 
medications was performed to attenuate the inherent drawbacks of the nonrandomized design. We 
found that initiation of statin treatment within 3 days after ischemic stroke was associated with 
lower mortality (hazard ratio, 0.67; 95% CI, 0.46–0.97) and a signal toward a (slightly) improved 
distribution of modified Rankin Scale at 90 days (hazard ratio, 1.21; 95% CI, 0.98–1.50). There was no 
increased risk of acute or postacute intracerebral hemorrhage among statin users. In contrast to the 
ASSORT population, we confined our analysis to statin-naive patients and were able to analyze more 
severely affected patients, with median National Institutes of Health Stroke Scale 11. 
 
We agree that further trials are desirable to test the effect of early statin administration, especially 
in combination with revascularization therapies. However, it is challenging to conduct such a 
randomized controlled trial with reasonable efforts and costs for several reasons. First, it is common 
practice in many stroke centers to start statin treatment already during (increasingly short) 
hospitalization. Moreover, the high prevalence of premorbid statin use and the lack of an 
intravenous statin formulation to treat severely affected patients reduce the chance to enroll a 
suitable target population to prove a beneficial effect of statins on stroke recovery. 
 To conclude, we would like to point out that, currently, there seems to be no reasonable argument 
to delay statin treatment given the preclinical and observational data and the reassuring safety 
results from ASSORT and STARS. Moreover, we would like to highlight that open clinical trial 
registries like Virtual International Stroke trials Archive offer the unique opportunity to perform or 
confirm estimation of effect sizes of a given intervention before the start of an extensive randomized 
controlled trial. 
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